Background and Purpose: Immune checkpoint inhibitors (ICIs) have improved outcomes in non-small cell lung cancer (NSCLC),yet durable benefit is limited to a subset of patients. Reliable predictive biomarkers are therefore essential. We reviewed genomic,proteomic, and metabolomic studies to evaluate how multi-omics integration advances prediction of ICI efficacy in NSCLC.Methods: A systematic search of PubMed, ClinicalTrials.gov, and Google Scholar was conducted on April 11, 2024, covering studiespublished from 2016 through January 2025, to identify omics-based biomarkers of ICI response in NSCLC. In total, 33 genomic, 9proteomic, and 9 metabolomic studies met inclusion criteria. Each was evaluated using a standardized evidence rubric (0–14) assessingeffect robustness, validation, cohort size, and clinical endpoint relevance.Results: Genomic predictors of poor response included EGFR and ALK/RET/ROS1 fusions, as well as KRAS co-mutations withSTK11, KEAP1, or SMARCA4, all linked to immune-cold phenotypes with low tumor mutational burden (TMB) and poor T-cellinfiltration. In contrast, KRAS/TP53 co-mutations, NOTCH family alterations, and BRAF V600E aligned with immune-hot signaturescharacterized by interferon signaling, PD-L1 upregulation, and cytotoxic T-cell infiltration. Proteomic studies consistently identifiedchemokines CXCL9 and CXCL10, apoptotic regulators (CASP8, FASLG), and checkpoint proteins (soluble PD-1, PD-L1, LAG-3) aspredictive, while acute-phase proteins (SAA1/2, S100A8/9) correlated with resistance. Multi-analyte platforms such as PROphetdemonstrated promising risk-stratification potential. Metabolomic profiling linked ICI benefit to higher baseline tryptophan, histidine,and short-chain fatty acids, while resistance was associated with increased 3-hydroxyanthranilic acid, pyruvate, and lipid metabolitesindicating immunosuppressive IDO pathway activity.Conclusion: Multi-omics approaches converge on pathways governing antigenicity, interferon signaling, and immune-metabolic crosstalk.Although promising, most biomarkers require prospective validation in large, uniformly treated cohorts. Integrative strategies—particularlywhen combined with AI-driven analytics—hold potential to refine patient stratification and guide clinical use of ICIs in NSCLC
Background and Purpose: Immune checkpoint inhibitors (ICIs) have improved outcomes in non-small cell lung cancer (NSCLC),yet durable benefit is limited to a subset of patients. Reliable predictive biomarkers are therefore essential. We reviewed genomic,proteomic, and metabolomic studies to evaluate how multi-omics integration advances prediction of ICI efficacy in NSCLC.
Methods: A systematic search of PubMed, ClinicalTrials.gov, and Google Scholar was conducted on April 11, 2024, covering studiespublished from 2016 through January 2025, to identify omics-based biomarkers of ICI response in NSCLC. In total, 33 genomic, 9proteomic, and 9 metabolomic studies met inclusion criteria. Each was evaluated using a standardized evidence rubric (0–14) assessingeffect robustness, validation, cohort size, and clinical endpoint relevance.
Results: Genomic predictors of poor response included EGFR and ALK/RET/ROS1 fusions, as well as KRAS co-mutations withSTK11, KEAP1, or SMARCA4, all linked to immune-cold phenotypes with low tumor mutational burden (TMB) and poor T-cellinfiltration. In contrast, KRAS/TP53 co-mutations, NOTCH family alterations, and BRAF V600E aligned with immune-hot signaturescharacterized by interferon signaling, PD-L1 upregulation, and cytotoxic T-cell infiltration. Proteomic studies consistently identifiedchemokines CXCL9 and CXCL10, apoptotic regulators (CASP8, FASLG), and checkpoint proteins (soluble PD-1, PD-L1, LAG-3) aspredictive, while acute-phase proteins (SAA1/2, S100A8/9) correlated with resistance. Multi-analyte platforms such as PROphetdemonstrated promising risk-stratification potential. Metabolomic profiling linked ICI benefit to higher baseline tryptophan, histidine,and short-chain fatty acids, while resistance was associated with increased 3-hydroxyanthranilic acid, pyruvate, and lipid metabolitesindicating immunosuppressive IDO pathway activity.
Conclusion: Multi-omics approaches converge on pathways governing antigenicity, interferon signaling, and immune-metabolic crosstalk.Although promising, most biomarkers require prospective validation in large, uniformly treated cohorts. Integrative strategies—particularlywhen combined with AI-driven analytics—hold potential to refine patient stratification and guide clinical use of ICIs in NSCLC